Getting CAR-T at a Government Hospital: Subsidies and Waiting Lists

Partly, and never automatically. India has no national scheme that pays for a CAR-T product by name. A government or grant-in-aid institution mainly reduces the hospital side of the bill and opens access to welfare funds. The cell product itself is normally still met from relief-fund sanctions, charitable funds and the family’s own money.

The single most useful thing to understand is that a CAR-T bill is really two bills sitting side by side, and a public hospital only moves one of them.

The first bill is the cell product. Its price is set by the manufacturer, and it is broadly the same wherever the product is infused. A government hospital does not manufacture it and does not discount it. The second bill is everything the hospital itself does — the eligibility work-up, the cell collection, the lymphodepleting chemotherapy, the admission, any intensive-care days, the supportive medicines, the repeat scans. That second bill is where institutional rates matter enormously, and it is not small.

There is a third thing a public or grant-in-aid institution carries that most corporate hospitals do not: a medical social work or patient welfare department whose job is to assemble funding for a patient from several sources at once. For a CAR-T family, that department is often worth more than the rate card.

This is the least documented part of CAR-T in India, and that is exactly why it matters. No public institution publishes a CAR-T rate card. No government portal lists which centres provide it. Everything below is about how to find out for your own case rather than what a search result says the price is.

No single scheme covers it. Families assemble the money from several sources at once: the Health Minister’s Cancer Patient Fund under Rashtriya Arogya Nidhi, a relief-fund grant, hospital welfare and charitable trusts, and personal or crowdfunded money. Ayushman Bharat’s annual cover is far below the product price.

Each of these routes has a different owner, a different form and a different timeline. They are independent of one another, which is the single most important practical fact on this page: they can and should be applied for at the same time.

You apply through the treating institution, not directly to a ministry. A haematologist confirms eligibility, the centre issues a written itemised estimate, and the hospital’s medical social work department files the applications. Sanctions are released to the hospital, not to the family. Start the paperwork at the work-up stage.

Families lose more time here than anywhere else in the pathway, almost always for the same two reasons: they wait for the medical decision to be final before starting the paperwork, and they file one application at a time.

1. Settle whether the diagnosis is even in the approved category. India’s approved CAR-T products cover CD19-positive relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia, in patients aged 15 and above with at least one prior line of therapy. Nothing else in the pathway matters until this is confirmed.
2. Obtain a referral to an accredited cell-therapy centre. Your haematologist or medical oncologist makes it. There is no self-referral route into CAR-T anywhere in India.
3. Complete the eligibility work-up at that centre — CD19 confirmation on flow cytometry or immunohistochemistry, imaging, marrow studies, and cardiac, renal, liver and lung function tests.
4. Ask for a written, itemised estimate on hospital letterhead. Every scheme and relief-fund application needs one, and none of them moves without it. The estimate should separate the product from the hospital charges.
5. Meet the medical social worker in the same week. This is the step families skip. That department knows which funds the institution can reach, what each one needs, and which of them are currently exhausted.
6. Assemble the documents once, for all applications: income or BPL certificate, ration card, Aadhaar, residence proof, the treating doctor’s certificate and the estimate, the diagnosis and pathology reports, and any Ayushman or state scheme card.
7. File in parallel, not in sequence. HMCPF, relief-fund and charitable applications are independent of one another. Waiting for one decision before filing the next is the commonest reason a family misses a manufacturing slot.
8. Track every sanction in writing and keep the estimate current. Estimates go stale, and a sanction issued against an expired estimate is returned for revision.

The step-by-step referral route into a cell-therapy centre, including what the centre asks for and why referrals are sometimes declined, is set out in Applying for CAR-T: The Referral Pathway Step by Step.

There is no published national waiting list. The wait is made of separate queues that mostly run one after another: a referral appointment, an eligibility work-up, funding clearance, an apheresis and manufacturing slot, manufacturing itself, and a bed with intensive-care backup. Funding clearance is usually the longest and least predictable stage.

Understanding it as several queues rather than one changes what a family does with the first fortnight. Two of these queues can be worked on at the same time; the rest cannot start until the one before it finishes.

What the queue does to the disease

• The disease does not pause while the paperwork moves. Teams commonly use bridging treatment to hold the disease during the wait. That is planned, not improvised.
• If the disease outruns the queue, the plan changes. A team may conclude CAR-T is no longer realistic. This is a real and reasonably common outcome, and it is the strongest argument for starting funding applications during the work-up.
• Two queues can be run at once. The eligibility work-up and the funding applications are independent. Running them together is the single biggest time saving available to a family.
• Keep more than one door open where the family can. Some families pursue a public centre and a private centre in parallel until one confirms both a slot and the funding.
• Ask at every review what the current bottleneck is. The answer changes week to week, and it tells you where to push.

Two CAR-T products hold Indian marketing authorisation. NexCAR19 (talicabtagene autoleucel), from ImmunoACT, was approved by the CDSCO in October 2023. Qartemi (varnimcabtagene autoleucel), from Immuneel Therapeutics, was approved in January 2025. Both target CD19. Both can be given only at accredited cell-therapy centres.

The public institution most closely associated with CAR-T in India is Tata Memorial Centre in Mumbai, a grant-in-aid institution where the first trial infusion of what became NexCAR19 was given in June 2021, as reported by the National Cancer Institute in February 2024. Indian news reporting during 2025 described SMS Hospital in Jaipur starting a dedicated government CAR-T service. Other public, grant-in-aid and non-profit institutions have since started programmes of their own.

There is an honest caveat to state plainly: no official national list of Indian CAR-T centres is published by the CDSCO or the health ministry, and the picture changes as programmes open. Three reliable ways to check the current position are to ask your treating haematologist for an up-to-date referral list, to ask the product’s manufacturer which centres they currently supply, and to check whether the institution is a National Cancer Grid member centre running a cell-therapy programme.

On price context, published sources put the Indian products far below international prices. The National Cancer Institute reported in February 2024 that NexCAR19 was expected to cost around 50,000 US dollars against roughly 400,000 US dollars for a CAR-T infusion in the United States. When Qartemi was approved, Immuneel indicated a price of around 60,000 US dollars per dose, reported by AABB in January 2025. Indian coverage has since quoted totals in the range of 30 to 50 lakh rupees at Indian centres. All of these are indicative, as of August 2026, from published sources — not a hospital rate card, and not a CION rate. CION Cancer Clinics does not price, supply or administer any CAR-T product.

Whether a second approved product changes the access picture, and how the two compare on approval, indication and reported price, is covered in Qartemi: India’s Second Approved CAR-T Therapy.

Approval status for any molecule in India is recorded in the CDSCO new-drug approval listing, checked August 2026. No CAR-T product other than the two named above holds an Indian marketing authorisation at that date; the imported products families read about are not routinely marketed here. If you are told otherwise about a third product, treat the status as unconfirmed until the treating centre shows you the approval.

If the immediate question is what a scheme or insurer will actually pay against a named product, Insurance and Scheme Coverage for CAR-T by Product goes through it product by product, including where cover stops.

If the question is procedural — who refers, what the centre asks for, and what happens at each visit — read Applying for CAR-T: The Referral Pathway Step by Step. If you are weighing the two Indian products against each other, Qartemi: India’s Second Approved CAR-T Therapy sets out how the second approval compares.

For the wider view across checkpoint inhibitors, biosimilars and the other classes of immune treatment — the medicines CION does deliver — start from Immunotherapy Medicines Explained, or from the main immunotherapy section.